Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer by Khelwatty, Said Abdullah et al.
Oncotarget1704www.oncotarget.com
www.oncotarget.com                                  Oncotarget, 2019, Vol. 10, (No. 18), pp: 1704-1715
Co-expression and prognostic significance of putative CSC 
markers CD44, CD133, wild-type EGFR and EGFRvIII in 
metastatic colorectal cancer
Said Abdullah Khelwatty1, Sharadah Essapen1,2, Izhar Bagwan3, Margaret Green3, 
Alan M. Seddon1 and Helmout Modjtahedi1
1School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston, UK
2St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK
3Department of Histopathology, Royal Surrey County Hospital, Guildford, Surrey, UK
Correspondence to: Helmout Modjtahedi, email: H.Modjtahedi@Kingston.ac.uk
Keywords: CSC; colorectal cancer; EGFR; immunohistochemistry
Received: January 15, 2019 Accepted: February 15, 2019 Published: March 01, 2019
Copyright: Khelwatty et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC 
BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
The presence of colorectal cancer stem cells (CSCs) have been associated with 
tumour initiation and resistance to therapy. This study investigated the co-expression 
and prognostic significance of the CSCs biomarkers CD44 and CD133 with wild-type 
EGFR (wtEGFR) and EGFRvIII in colorectal cancer (CRC). The expression of these 
biomarkers were determined in tumours from 70 patients with metastatic CRC by 
immunohistochemistry, and in a panel of human CRC cell lines, and their variants 
with acquired-resistance to EGFR inhibitors, by flow cytometry. The expression of 
CD44, CD133, wtEGFR and EGFRvIII were present in 17%, 23%, 26% and 13% of 
cases and the co-expression of CD44/CD133 with wtEGFR and EGFRvIII were present 
in 9% and 3% of the cases respectively. Only co-expression of CSCs/EGFRvIII (P = 
0.037), and amphiregulin (P = 0.017) were associated with worse overall survival. 
Interestingly, disease-free survival was improved in BTC expressing patients (P = 
0.025). In vitro CD133 expression and its co-expression with CD44 were associated 
with primary-resistance to irinotecan and acquired-resistance to anti-EGFR inhibitors 
respectively. Our results suggest co-expression of CSCs and EGFRvIII could be 
potential biomarkers of worse overall survival and resistance to therapy in patients 
with mCRC and warrants further validation in a larger cohort.
INTRODUCTION
Colorectal cancer (CRC) remains ones of the leading 
causes of cancer deaths worldwide. Currently, CRC is 
estimated to be the third most commonly diagnosed cancer 
(140,250) and the third leading cause of cancer deaths 
(50,630) in the USA [1], highlighting the need for the 
development of more effective and less toxic therapeutic 
agents. The traditional model of tumourigenesis has 
been based on the idea that every cell within the tumour 
population is capable of tumour initiation and propagation. 
However, in the last decade with the emergence of the 
cancer stem cell (CSCs) hypothesis, it is postulated that 
a small fraction of cells are capable of tumour initiation 
and propagation and their presence are associated with a 
more aggressive tumour type [2–8]. Colorectal CSCs are 
characterised by the expression of CD133 positive cells [2, 
4] and increasingly other surface markers such as CD44, 
Lgr5, EpCAM have been included in this profile [9–17].
Since the early 1980s, aberrant expression of the 
epidermal growth factor receptor (EGFR) has been widely 
reported in a range of epithelial malignancies including 
colorectal cancer. As such the EGFR remains an important 
therapeutic target for therapy with anti-EGFR monoclonal 
antibodies (mAbs) cetuximab and panitumumab, which 
have been incorporated into treatment paradigms 
for patients with refractory metastatic CRC [18–22]. 
However, a major challenge is intrinsic drug-resistance 
and/or acquired-resistance following a short course of 
therapy in patients with CRC. Indeed, RAS mutations have 
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served as an important negative predictive biomarker for 
the primary resistance to therapy with anti-EGFR mAbs 
in patients. In another study, the CD133 was found to be 
increased in CRCs that are hyper-activated by mutations 
in the RAS-RAF-MEK-ERK pathways (Kemper et al., 
2012). However, not all patients with wild type KRAS 
respond to therapy with anti-EGFR mAbs [23, 24] and 
objective responses of up to 44% have been reported 
in mCRC patients with KRAS mutations treated with 
FOLFIRI plus cetuximab in other studies [25].
To our knowledge, there are currently no studies 
on the co-expression and prognostic value of the putative 
CSCs biomarkers CD44, CD133, the wtEGFR and its 
heterologous ligands, and the type III-EGFR mutant 
(i.e. EGFRvIII) in patients with mCRC. Therefore, in 
this study using specific antibodies, we investigated the 
prognostic value of the co-expression of CD44, CD133, 
EGFRvIII, wtEGFR, and EGFR ligands in tumour 
specimens from 70 mCRC patients. We also investigated 
the expression levels of CD44, CD133 in a large panel 
of CRC cell lines and their association with response to 
treatment with standard cytotoxic drugs and the EGFR 
inhibitors. Moreover, using CRC cells and their drug-
resistant variants, we investigated the role of CD44 and 
CD133 in the development of acquired-resistance to the 
EGFR inhibitors.
RESULTS
Clinicopathological features
Patient clinicopathological characteristics are 
summarised in Table 1. The median patient follow-up time 
was 4 years. None of the patients had received radiotherapy 
or chemotherapy prior to surgery. Forty three patients 
received post-operative adjuvant chemotherapy. Patients 
with tumours of N2 stage were found to have a shorter 
overall survival (P = 0.004) and disease-free survival (P 
= 0.0003). No significant association was found between 
survival and the other prognostic factors (Table 1).
Immunohistochemical expression of CD44, 
CD133, EGFRvIII, wtEGFR and ligands in 
colorectal tumors
The expression of CD44 and CD133 was 
determined in all 70 Dukes’ C and D colorectal cases 
by immunohistochemistry. The pattern of CD44 
immunostaining was found to be membranous and low 
and high expression in 83% and 17% of the patients 
respectively (Figure 1A and Table 2A). CD133 was found 
to stain the luminal border with immunostaining present 
in necrotic debris in well differentiated tumours and a dot-
like staining in poorly differentiated tumours with 23% 
and 77% of the cases expressing high and low levels of 
CD133 staining (Figure 1B and Table 2A).
At cut-off value of >5%, wtEGFR expression 
was membranous in 26%, while EGFRvIII expression 
was observed predominantly in cytoplasm in 13% of 
the colorectal patients (Figure 2A and Table 2B). Of the 
EGFR ligands, amphiregulin, BTC, EGF, and TGFα were 
expressed in the cytoplasm of 50%, 76%, 70%, and 73% 
of the tumours respectively (Figure 2A and Table 2B). 
Immunohistochemical expression of epiregulin, HBEGF, 
and epigen were undetectable in this study.
Of the 70 CRC patients examined, 36% expressed at 
least one of the CSC markers (CD44 or CD133). However, 
the co-expression of CD44 or CD133 with EGFRvIII and 
wtEGFR was found in only 3% and 9%, respectively. At 
cut-off value >5%, 17/70 patients were found to co-express 
wtEGFR with at least one ligand while 11/70 patients co-
expressed wtEGFR with all 4 ligands (Table 2B).
CD133, EGF and TGFα expression is 
significantly associated with clinicopathological 
parameters
The expression of CSCs, EGFRvIII, wtEGFR 
and its ligands was analysed against clinicopathological 
characteristics of patients using Chi-squared and Fisher 
Exact tests. A significant association was found between the 
expression of CD133H and tumours with <G3 differentiation 
(P = 0.019). At cut-off value >50%, the expression of TGFα 
was also significantly associated with tumours <G3 (P = 
0.028). Interestingly, EGF expression above a cut-off value of 
50% was significantly associated with M1 stage (P = 0.002).
EGFRvIII, amphiregulin, and BTC is 
significantly associated with survival
A significant association was found between 
EGFRvIII (P = 0.005) and amphiregulin (P = 0.017) 
expressions at cut-off value of >50% and shorter overall 
survival (Figure 2B). Univariate analysis found a 4.5 fold 
and 2 fold increased risk of a shorter overall survival with 
expression of EGFRvIII (P = 0.016) and amphiregulin (P 
= 0.04), respectively and remained independent prognostic 
indicators of survival when analysed in multivariate 
analysis in this study (Table 3).
The expression of BTC at cut-off value of >50% was 
found to be significantly associated with longer disease-
free survival (P = 0.025) (Figure 2B) and multivariable 
analyses showed that BTC expression was an independent 
prognostic indicator of favourable disease-free survival 
(HR = 0.369, CI = 0.150 – 0.910, P = 0.03) in these 
patients (Figure 2B and Table 3).
Interestingly, the co-expression of CD44 or CD133 
with EGFRvIII was significantly associated with shorter 
overall survival (P = 0.037) and remained an independent 
prognostic indicator of overall survival when adjusted for 
multivariable effect (HR = 5.451, CI = 1.193 – 24.906, P 
= 0.029) (Table 3).
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CD44 and CD133 expression in human colorectal 
tumor cell lines
The cell surface expression of CD44 and CD133 
was determined by flow cytometry in reference to positive 
control cell lines (Figure 3A). Of the human colorectal 
tumour cell lines examined in this study, HCT116, HT29, 
CCL-228 and DiFi cells were highly CD44 positive (i.e. 
>95% of tumour cell populations), while CCL-225 and 
Colo-2 cells were CD44 negative (Figure 3A). CD133 
positive cell population was much lower in the majority of 
colorectal tumour cells, with only CaCo-2 cells expressing 
CD133 in more than 95% of the cells (Figure 3A).
Association between expression of CD44 and 
CD133 and response to treatment with cytotoxic 
drugs
We have reported previously the growth response 
of human colorectal tumour cell lines to treatment with 
Table 1: Patient clinicopathological characteristics and their association with overall survival and 
disease free survival using Kaplan-Meier analysis and log-rank Chi-squared test in 70 metastatic 
colorectal cancer patients
Characteristics N OS in years
(mean ± SE)
95% CI P-value
(χ2-test)
DFS in months
(mean ± SE)
95% CI P-value
(χ2-test)
Age in years
≤70 19 5.478 ± 0.527 4.446–6.511 NS 58.737 ± 8.250 42.567–74.907 NS
>70 51 5.785 ± 0.361 5.078–6.492 81.460 ± 6.288 69.136–93.785
Gender
Male 40 5.930 ± 0.415 5.117–6.743 NS 78.636 ± 7.630 63.682–93.590 NS
Female 30 5.476 ± 0.450 4.593–6.359 75.558 ± 8.212 59.464–91.653
Tumour Site
Right colon 35 5.600 ± 0.449 4.720–6.480 NS 78.968 ± 8.184 62.927–95.008 NS
Left colon 35 5.843 ± 0.419 5.022–6.663 77.017 ± 7.269 62.770–91.265
T stage
T4 18 5.477 ± 0.695 4.116–6.839 NS 71.000 ± 9.247 52.876–89.124 NS
<T4 52 5.783 ± 0.342 5.113–6.453 76.092 ± 6.519 63.315–88.868
N stage
N2 41 3.971 ± 0.308 3.368–4.574 0.004 36.489 ± 4.702 27.273–45.706 0.0003
<N2 19 6.047 ± 0.329 5.401–6.693 88.842 ± 5.839 77.397–100.286
M stage
M0 62 5.832 ± 0.315 5.214–6.450 NS 79.917 ± 5.951 68.252–91.581 NS
M1 8 4.208 ± 0.601 3.031–5.386 45.429 ± 6.432 32.822–58.035
LVI
Absent 48 5.949 ± 0.349 5.265–6.632 NS 82.441 ± 6.933 68.851–96.030 NS
Present 22 5.142 ± 0.568 4.029–6.255 57.516 ± 6.191 45.381–69.650
Grade
G3 41 5.869 ± 0.464 4.960–6.779 NS 74.818 ± 7.324 60.463–89.173 NS
<G3 29 5.592 ± 0.408 4.792–6.392 79.061 ± 8.776 61.860–96.262
Chemotherapy
No 17 5.250 ± 0.618 4.040–6.460 NS 58.063 ± 8.071 42.244–73.881 NS
Yes 43 6.012 ± 0.450 5.257–6.766 80.511 ± 6.888 67.010–94.011
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Table 2: Immunohistochemical expression of (A) CD44, CD133, (B) wtEGFR, EGFRvIII and 
EGFR ligands and their co-expressions in 70 metastatic colorectal cancer patients
A
Variables
No. of positive tumours (%)
% Positive tumour cells Location
0–50 (Low) >50 (High) Mem Cyto Luminal
CD44 58 (83) 12 (17) 70 (100)  - -
CD133 54 (77) 16 (23) - - 70 (100)
Abbreviations: Mem, Membranous; Cyt, Cytoplasmic.
B
Variables
No. of positive tumours (%)
% Positive tumour cells Intensity Location
>5 >10 >20 >50 1+ 2+ 3+ Mem Cyto
wtEGFR 18 (26) 12 (17) 9 (13) 4 (6) 15 (21) 2 (3) 1 (1) 17 (24) 2 (3)
EGFRvIII 9 (13) 5 (7) 4 (6) 4 (6) 9 (13) - - - 9 (13)
Amphiregulin 35 (50) 4 (6) 11 (16) 20 (29) 26 (37) 14 (20) - - 35 (50)
BTC 53 (76) 3 (4) 14 (20) 40 (57) 45 (64) 25 (36) - - 53 (76)
EGF 49 (70) 6 (9) 5 (7) 34 (49) 36 (51) 25 (36) - - 49 (70)
TGFα 51 (73) 2 (3) 7 (10) 39 (56) 47 (67) 4 (6) - - 51 (73)
wtEGFR/1 ligand 11 (16) - - - - - - - -
wtEGFR/1 or more 
ligands
17 (24) - - - - - - - -
Any CSC/wtEGFR 6 (9) - - - - - - - -
Any CSC/EGFRvIII 2 (3) - - - - - - - -
Abbreviations: Mem, Membranous; Cyt, Cytoplasmic.
Figure 1: Immunohistochemical staining of the metastatic colorectal cancer specimens for CD44 and CD133 expression showing the 
intensity of staining (A),  and the cellular location of staining  (B).
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anti-EGFR mAb ICR62 and cytotoxic drugs [26]. Of the 
cell lines examined, only the EGFR overexpressing DiFi 
cells were highly sensitive to treatment with anti-EGFR 
mAb ICR62. We found no significant association between 
the expression of CD44 and/or CD133 and response to 
treatment with anti-EGFR mAb ICR62, irreversible ErbB 
inhibitor afatinib, and reversible ErbB inhibitors erlotinib 
and gefitinib (data not shown). Of the cytotoxic drugs, no 
significant association was found between the expression 
of CD44 and/or CD133 and response to treatment with 
5FU or Oxaliplatin. Interestingly, there was a significant 
association between the expression of CD133, and its co-
expression with CD44 and resistance to treatment with 
irinotecan (Figure 3B).
We reported previously development of the 
EGFR overexpressing DiFi cell variants with acquired 
resistance to the anti-EGFR mAb ICR62, and TKI 
gefitinib [27]. Interestingly, we found the expression 
of CD44 to be significantly increased in both resistant 
variants DiFi62 and DiFiG cells (Figure 3C). CD133 
expression, on the other hand was significantly increased 
only in DiFiG cells.
Figure 2: Immunohistochemical expression of wtEGFR, EGFRvIII, and EGFR ligands (A), association between the expression of 
wtEGFR, amphiregulin and BTC and survival shown with Kaplan Meier curves (B) in 70 metastatic colorectal cancer patients.
Table 3: The association of expression of EGFRvIII, amphiregulin with overall survival (OS) and 
BTC with disease-free survival in 70 metastatic colorectal cancer patients using multivariate Cox 
regression analysis
Overall Survival (OS)
Variables
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
EGFRvIII 4.568 1.325–15.748 0.016 7.215 1.941–26.817 0.003
Amphiregulin 2.070 1.035–4.139 0.04 2.082 1.040–4.167 0.038
Disease-free Survival (DFS)
Variables Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
BTC 0.375 0.153–0.920 0.032 0.369 0.150–0.910 0.030
P-value of ≤0.05 was considered significant.
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Figure 3: Expression of CD44 and CD133 in human colorectal tumour cell lines (A), association between CD133 expression and treatment 
with irinotecan (B), expression of CD44 and CD133 in DiFi parental versus DiFi62 and DiFiG acquired resistant variant cells (C), ±SD 
determined by flow cytometery (n = 3).
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DISCUSSION
CSC are characterised by slow proliferation and cell 
cycle and as such have been associated with resistance to 
anticancer therapies through the deployment of various 
defence mechanisms such as activation of anti-apoptotic 
proteins, efflux pumps, and quiescence [28]. Because 
conventional chemotherapies target rapidly growing cells, 
initial treatment response in the form of tumour shrinkage 
is seen but they fail to eradicate the cancer as the tumour 
initiating CSCs are spared.
In this study, we have evaluated the association 
between the co-expression of putative CSC markers 
CD44, CD133, which have been shown to identify 
cells with tumour initiating and progression properties 
[3–7, 29]. Our findings suggest that despite putative 
CSC markers CD44 and CD133 being expressed 
commonly and the expression of CD133 being associated 
significantly with well and moderately differentiated 
tumours, there was no significant association with patient 
outcome in this study. Indeed, the prognostic significance 
of CD44 and CD133 in patients with CRC has been 
investigated in several studies [11, 30–33]. However, 
to our knowledge only four studies have investigated 
the combined expression and prognostic significance 
of both CD44 and CD133 in CRC patients using IHC 
and found contradicting results. Horst and colleagues 
investigated the expression of CD44, CD133 and CD166 
in 110 CRC patient tumours by IHC and found 33%, 
52% and 64% of the cases positive respectively. The co-
expression of all three markers was found in 36% of the 
cases and concluded CD133 to be the best sole marker to 
predict low patient survival [32]. Another study, which 
investigated the expression of CD24, CD44 and CD133 
in 523 tissue microarrays from CRC patients by IHC, 
found CD24, CD44 and CD133 expression in 51%, 96% 
and 25% of the cases examined respectively. Although 
the study found CD133 expression to be associated with 
gender and advance T-stage, no significant association 
was found between expression of CD44 and CD133 and 
survival [30]. Furthermore, Lugli and colleagues using 
TMA evaluated 1420 primary CRC and 57 normal mucosa 
samples for the expression of CD133, CD44s, CD166, 
EpCAM, and ALDH1 but failed to find any association 
between expression of these markers and patient outcome 
[34]. More recently, another study conducted by Jing et al. 
(2015) examined 36 colorectal primary adenocarcinomas 
with synchronous hepatic metastasis and found CD44, but 
not CD133, expression was independent factor associated 
with survival [35]. Finally, the results of two recent meta-
analyses of 65 studies have also indicated that the high 
expression of CD133 is associated with poorer 5year 
overall survival and disease-free survival highlighting 
that CD133 could serve as a predictive biomarker of poor 
prognosis and treatment failure as well as a potential 
therapeutic target in patients with mCRC [36, 37].
One of the findings of the present study was that 
the co-expression of CSCs and EGFRvIII was found to 
be an independent factor associated with worse overall 
survival, albeit in a small number of patients. EGFRvIII 
is a ligand-independent, mutated form of the EGFR and 
its expression has been associated with poor prognosis 
in several human cancers [38–40]. To our knowledge, 
there have been no other studies on the co-expression 
of CSCs and EGFRvIII, wtEGFR and its ligands in 
patients with mCRC and as such this is a novel finding 
and warrants further investigation in a larger cohort of 
mCRC patients. The aberrant expression of EGFR and 
its ligands have been associated with poor outcome 
to therapy in various human malignancies, including 
CRC [38, 41–44]. In the present study while we did not 
find any association between the wtEGFR expression 
and survival, expression of amphiregulin was found to 
be a significant independent factor for poorer overall 
survival in these patients, which was consistent with 
the findings of other studies [45–49]. Interestingly, we 
found BTC expression to be a significantly associated 
with a favourable outcome in patients with mCRC. 
However, more recently, another study conducted by 
Yun et al. that examined 331 CRC for the association 
between the expression of EGFR family members and 
its ligands. While the study did not find any association 
between BTC expression and overall survival, they 
found the expression of HER4, another member of the 
EGFR family, to have a favourable outcome in patients 
with CRC [41]. BTC is known to also bind to HER4, 
which has been shown to be associated with better 
outcome in some cancers, including breast and gastric 
[50–52]. Indeed, the expression of HER4 although not 
determined in the present study, was determined in our 
previous study on the same cohort of patients with high 
expressions of HER4 (data not shown) [53]. This could, 
in part, provide an explanation for the association of BTC 
expression interacting with the overexpressed HER4 in 
these patients and contributing to a longer disease-free 
survival in the present study.
Nautiyal et al. investigated EGFR regulation of 
colon cancer stem-like cells (CD44, CD166 and ALDH-1 
positive cells) and found EGFR inhibition by anti-EGFR 
mAb cetuximab diminished age-related increase of CD166 
and ALDH-1 suggesting EGFR could have an important 
role in the regulation of colorectal CSC [54]. In this study, 
for the first time we investigated the expression of CD44 
and CD133 in a large panel of human colorectal tumour 
cell lines and determine association to sensitivity to 
treatment with anti-HER inhibitors and cytotoxic drugs. 
We found that CD44 expression is more common than 
CD133 expression in human colorectal tumour cell lines 
and patient samples. While we did not find any significant 
association between expression of CD44 and/or CD133 
and response to anti-EGFR mAb ICR62, and irreversible 
erbB inhibitor afatinib, reversible small molecule tyrosine 
Oncotarget1711www.oncotarget.com
kinase inhibitors erlotinib and gefitinib (data not shown), 
there was a significant association between CD133 
expression and its co-expression with CD44 and response 
to treatment with the cytotoxic drug irinotecan. These 
findings are in line with previous studies of other cancer 
types where the expression of CSCs were found to be 
associated with radio- and/or chemo-resistance in cancers 
of prostate, hepatocellular and breast [55–58]. In addition, 
we have also observed a significant increase in the 
expression of CD44 and CD133 in CRC tumour cells with 
acquired resistance to anti-EGFR mAb and TKI therapies 
further highlighting the role played by CSCs not only in 
primary drug resistance, but also in the development of 
acquired drug resistance. However, further studies are 
warranted and should confirm the possible link between 
expressions of CSCs and response to treatment with the 
EGFR inhibitors.
In conclusion, our results suggest that co-
expression of CSCs and EGFRvIII and the expression 
of amphiregulin are associated with poorer overall 
survival in patients with mCRC. However, expression 
of other ligands such as BTC, through its interactions 
with other EGFR family members such as HER4, could 
contribute to a longer disease-free survival in some 
mCRC patients. Since colorectal cancer was predicted 
to be the third most commonly diagnosed cancer and the 
second leading cause of cancer deaths worldwide in 2018 
[59], our results support the need for further studies and 
its validation on the prognostic significance of the co-
expression of CSCs, EGFRvIII, and the wtEGFR and 
its ligand and their predictive value for the response to 
therapeutic interventions in a larger group of patients 
with mCRC.
MATERIALS AND METHODS
Tumor cell lines
The human colorectal tumour cell lines CCL-221 
(Dukes’ C), CCL-225 (Dukes’ C), CCL-228 (Dukes’ B), 
CCL-244 (tumour stage unknown) and CCL-235 (Dukes’ 
D), CaCo-2 were purchased from the American Type 
Culture Collection (Manassas, VA) and HCT-116 (tumour 
stage unknown), HT-29 from European Collection of Cell 
Culture (Porton Down, United Kingdom). Other human 
colorectal tumour cell lines used in this study included our 
two cell lines Colo-2 (Dukes’ A) and Colo-13 (Dukes’ C) 
[60] and the EGFR over-expressing cell line DiFi which 
was established from a patient with familial adenomatous 
polyposis (FAP) and was kindly provided by Dr Z Fan 
(MD-Anderson Cancer Centre). Acquired drug resistant 
variants of DiFi cells were developed as described 
previously [27]. All cell lines were routinely cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Merck, 
Gillingham, UK) supplemented with 10% foetal bovine 
serum (FBS) (Merck, UK) and the antibiotics penicillin, 
streptomycin and neomycin and were maintained at 37°C 
in a humidified atmosphere with 5% CO2.
Antibodies, EGFR inhibitors and other reagents
The rat monoclonal antibody ICR62 (IgG2b) was 
raised against the external domain of the EGFR on the breast 
carcinoma cell line (MDA-MB468) [61]. The secondary 
antibody used in this study included FITC-conjugated rabbit 
anti-mouse IgG Star 9B (Bio-rad Antibodies, Kidlington, 
UK). The cytotoxic drugs, 5-FU, Irinotecan and Oxaliplatin 
were purchased from Merck, UK.
Flow cytometry
The cell surface expression level of CSC markers 
CD44 and CD133 in human colorectal tumour cell 
lines and drug resistant variants was determined using 
FACScalibur, employed for the determination of EGFR 
family members (Becton Dickinson, Oxford, UK) as 
described previously [26].
Patient information
Seventy patients with metastatic CRC (Dukes’ C 
and D) who underwent radical surgery at the Royal Surrey 
County Hospital (Guildford, UK) between April 2002 
and November 2007 were included in this retrospective 
study. Ethical approval was obtained from the Research 
and Development Committee of the Royal Surrey County 
Hospital. Those with no follow-up information, mis-
diagnosis, and incomplete histology were excluded. Cases 
of peri- and post-operative death (i.e. within 6 months 
of surgery) were also excluded from this study, as were 
those with tumour blocks in a condition too poor for 
immunohistochemical use. Detailed clinicopathological 
information, including patient age and gender was 
available for each patient.
Immunohistochemistry
Paraffin-embedded sections of tumour specimens 
(3 µM) and control cell pellets (Caco-2) were cut from 
paraffin-embedded blocks. IHC staining was carried 
out as described previously [53], using the following 
primary antibodies: mouse anti-wild-type EGFR (M7298) 
and mouse anti-human CD44 mAb (M7082) (Agilent, 
Stockport, UK), anti-EGFRvIII (BS-2558R), rabbit 
pAb anti-Amphiregulin (GTX100986, InsightBiotech, 
London, UK), mouse anti-EGF (AHP767), mouse anti-
TGFα (AHP284G) (Bio-Rad Antibodies, UK), mouse 
anti-Betacellulin (MAB2611) (Biotechne, Abingdon, 
UK), rabbit pAb anti-HBEGF (HPA053243), rabbit pAb 
anti-Epigen (HPA014420), and rabbit pAb anti-Epiregulin 
(HPA054373) (Merck, UK), and mouse anti-human 
CD133 (130-090-422) (Miltenyi Biotec, Surrey, UK).
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Scoring criteria
The immunostaining of the tumour sections were 
scored based on the percentage of tumour cells that had 
EGFR and/or ligands immunostaining (i.e. >5%, >10%, 
>20%, and >50%) and intensity of immunostaining (i.e. 
negative 0, weak 1+, moderate 2+ and strong 3+) and 
location (i.e. membrane, cytoplasm or nucleus of the cells). 
CD44 and CD133 sections were scored by the percentage 
of positive cells (0% to 50% and ≥50%) as low (L) and 
high (H), respectively. The immunostaining was scored 
by two independent observers without prior knowledge 
of the clinicopathological parameters and any disparity in 
scoring was resolved by simultaneous reassessment of the 
staining by both observers.
Statistical analysis
The relationship between the expression levels 
of CSCs and response to treatment was determined 
by linear regression analysis and changes in the 
expression of CSCs in drug resistant variants were 
tested by Paired T-test analysis. The association 
between immunohistochemistry scores and patient 
clinicopathological data was assessed using Chi-Squared 
test (Pearson Chi-Square) and Fisher Exact Test. Kaplan-
Meier survival plots were used to evaluate differences 
between groups by performing log rank-test. For 
univariate and multivariate analysis, the Cox regression 
model was used and P ≤ 0.05 was considered statistically 
significant. All statistical analyses were carried out using 
the PASW statistics 24 (SPPS Inc.).
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